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ABSTRACT
Objective: Apoptosis, or programed cell death, forms an important part of the cellular regulation machinery. The Bcl-2 protein family, comprising 
proapoptotic and antiapoptotic members, forms an important part of the cells internal apoptotic pathway. Overexpression of the antiapoptotic 
members of the family in a number of cancer cell lines renders them immune to apoptosis and the ability to survive under conditions of cellular stress. 
Inhibition of the antiapoptotic members of the Bcl-2 family like Bcl-XL is, therefore, an interesting target for the development of anticancer therapy.
Methods: The structure of antiapoptotic Bcl-XL receptor (1YSG) was taken from PDB database. The 23-dimensional structure of gallic acid analogs 
was designed. The Lipinski properties of gallic acid analogs were calculated using molsoft. Docking studies have been carried out through Autodock 
4.0 software.
Results: Molecular docking analysis with gallic acid and their structural analogs showed propyl gallate, benzyl gallate, diallyl gallate, phenyl ethyl 
gallate, and allyl gallate are more interactive and binding strongly than gallic acid at active site of Bcl-XL.
Conclusion: Further these five compounds should be considered as potential candidates for Bcl-XL inhibitor.
Keywords: Apoptosis, Bcl-2, Antiapoptotic Bcl-XL receptor, Gallic acid, Docking studies.
INTRODUCTION
Apoptosis is an important cellular process that causes death of the 
damaged cells [1]. Its malfunction can lead to cancer development [2]. 
There is growing facts that the processes of neoplastic alteration, 
sequence involve change in the normal apoptotic pathways [3]. 
Proteins in the Bcl-2 family are central regulators of programed cell 
death [4], and members that inhibit apoptosis, such as Bcl-XL and 
Bcl-2, are overexpressed in many cancers and contribute to tumor 
initiation, progression, and resistance to therapy [5]. Bcl-XL expression 
correlates with chemoresistance of tumor cell lines [6], and reductions 
in Bcl-2 increase sensitivity to anticancer drugs [7] and enhance 
in vivo survival [8]. The development of inhibitors of these proteins as 
potential anticancer therapeutics has been previously explored, but 
obtaining potent small molecule inhibitors has proved difficult owing 
to the necessity of targeting a protein–protein interaction.
In the recent years, traditional system of medicine emerged as a 
potential source to manage the growing rate of chronic, degenerative, 
environmental, lifestyle, and stress related diseases like cancer [9]. 
Among the most promising chemopreventive agents, certain natural 
polyphenols have recently received a great deal of attention because of 
their demonstrated inhibitory activity against tumorigenesis. In view of 
their anticancer properties, these compounds also hold great promise 
as potential chemotherapeutic agents [10].
One of a well-known polyphenol is gallic acid (3,4,5-trihydroxicbenzoic 
acid) which has selectively cytotoxic activity against a variety of 
tumor cells [11]. Gallic acid causes induction apoptosis in 3T3-L1 
preadipocytes [12] and several other cell lines. There are two pathways 
by which apoptosis takes place, the mitochondria-dependent (intrinsic 
pathway) and the death receptor-dependent (extrinsic pathway) [13]. 
Gallic acid significantly activates Fas, FasL, and p53 proteins [14]. 
Both the apoptosis pathways are regulated by Bcl-2 family proteins. 
Bcl-2 family proteins including proapoptotic proteins Bax, Bak, Bad 
and Bcl-XS and antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1. The 
ratio of expression of Bax/Bcl-2 is a decisive factor in determining 
apoptosis [13]. Through upregulation of Bax and downregulation of 
Bcl-2 gallic acid could induce apoptosis in 3T3-L1 preadipocytes [14]. 
Gallic acid-induced apoptosis in HeLa cells was accompanied by the 
slight downregulation of Bcl-2 and the upregulation of Bax [15]. Cory and 
Adams [16] indicated that mitochondrial release of cytochrome c can be 
controlled by the Bcl-2 family of proteins. Cells treated with gallic acid 
showed significantly downregulated Bcl-XL protein and upregulation of 
Bak and Bad proteins [14].
The objective of gallic acid analogs design is to obtain compounds 
which more potent and has more specific activity as Bcl-XL inhibitor. 
Nuclear magnetic resonance structural analysis of the Bcl-XL/Bak 
BH3 peptide complex showed that the Bak BH3 domain binds to the 
hydrophobic cleft formed by the BH1, BH2, and BH3 domains of Bcl-
XL [17]. It can be concluded that the part of binding pocket of Bcl-XL 
protein is hydrophobic. Gallic acid analogs designed by methylation 
and esterification with allyl or alkyl is aimed to make a novel compound 
which has more hydrophobic characteristic than lead compound. These 
new analogs are expected to have more hydrophobic interactions with 
the protein Bcl-XL.
Conventional drug design techniques are based on trial and error testing 
using cells or animals. High-throughput screening for chemicals with 
desired bioactivities requires specialized labs that make the process 
costly. With a growing number of known experimental structures of 
target molecules, computational methods have been used successfully 
to supplement and speed up drug discovery. Computer-based molecular 
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design combines methods of informatics, medicine, and biophysics. This 
cross-disciplinary field has accelerated drug research by predicting 
the potential therapeutic effectiveness of designed molecules before 
laboratories experiments and costly preclinical trials. In addition, 
computational modeling has led to discoveries of structures of a novel 
small molecule [18]. In this work, informatics and computational design 
were used to evaluate gallic acid analogs that could potentially promote 
the death of cancer cells Apoptosis by inhibition of Bcl-XL protein.
METHODS
Protein preparation
The structure of the antiapoptotic Bcl-XL receptor was taken from 
PDB (1YSG-pdb id). The ligands and crystallographic water molecules 
were removed from the protein, and the chemistry of the protein was 
corrected for missing hydrogen atoms. Following the above steps of 
presentation, the protein was subjected to energy minimization using 
Python Molecular Viewer 1.5.6 cr3 [19].
Gallic acid analogs (ligand) structures preparation
The 2D structure of each ligand is displayed as an image generated by 
MarvinSketch 5.10.0 (ChemAxon) [20]. The 2D chemical structure 
constructed in the ligand design page by the user is converted to a 3D 
structure. The 3D ligand structure then undergoes geometry optimization 
to produce the initial ligand structure. The 2D to 3D transformation, 
geometry optimization, and molecular format transformation are 
performed by OpenBabel 2.3.0. The analogs were designed by 
methylation and esterification of carboxylate groups and hydroxyl 
groups, respectively. The structures analogs as shown in Table 1.
Drug likeliness evaluation
The drug likeliness of the compounds was evaluated with the help 
of Lipinski drug filter under Molsoft. This rule describes molecular 
properties important for a drug’s pharmacokinetics in the human 
body and provides the information regarding the utilization of the 
ligands as a drug. A promising drug candidate should be “drug-like,” 
which means that it should have characteristics similar to known 
drugs. Bioavailability, protein affinity, toxicity, transport, absorption, 
and metabolic stability of a compound depend on many factors. These 
factors include the compound’s hydrophobicity, electronic distribution, 
hydrogen bonding, molecule size, and flexibility.
Molecular docking of complexes Bcl-XL and gallic acid analogs
The preparative protein and ligand coordinates were saved as pdbqt 
files. The third step is molecular docking. Grid maps of the predefined 
active site for each atom type present in the ligand are calculated by 
AutoGrid before docking a ligand to the target Bcl-XL. After assigning 
Gasteiger partial charges to the atoms in the ligand, the Lamarckian 
genetic algorithm based molecular docking and calculation of 
ligand/Bcl-XL dissociation constant are carried out by AutoDock 4.0 
Autodock 4.0 software [21]. The docking parameters are set as follows: 
The ligand translation step is set to 1.0A°, the ligand quaternion and 
torsion step are both set to 50°, the maximum number of energy 
evaluations is set to 1.0×106, the maximum number of genetic 
algorithm operations is set to 2.7×104, the number of individuals in 
the population is set to 150, the rate of mutation and crossover are 
set to 0.02 and 0.8, respectively. The ligands are set to have prepared 
as a rigid structure. The complex of protein and ligand are saved as 
output in dlg files, the grid box volume was adjusted to 40×40×40 Å in 
the x, y and z axes, respectively, for specific docking of complexes and 
grid-sizes have space up to 1 Å. Other parameters are all set as default. 
When searching the conformational and orientational spaces of the 
ligand with rotatable bonds having full flexibility, the structure of the 
Bcl-XL is kept rigid. For each docking evaluation, 10 independent runs 
are performed to evaluate different ligand poses, and only the most 
favorable pose is dumped to the results file. The results of complexes 




According to Lipinski, 2000 poor absorption and permeation are more 
likely to occur when the molecular weight is over 500, the octanol/
water partition coefficient is over 5 the number of hydrogen-bond 
acceptors (N and O atoms) is more than 10. As per the view of Smith 
and Lipinski, for this study, out of 23 gallic acid analogs, 5 compounds 
with best ΔG binding value are satisfying all the five rules evidencing 
that this five compounds are able to show drug likeliness.
In this study, five compounds have logP values ranging from 1.64 to 2.82 
(Table 2).
Docking results
The binding sites cavity on protein Bcl-XL is very spacious and located 
on the surface. Interaction in this binding sites are mainly hydrophobic 
and a little polar hydrogen bonding [22]. Ligand docked into binding 
site cavity of Bcl-XL. The docking energies of all compounds were 
represented as ΔG binding in kcal/mol (Table 3). Molecular docking 
provides information on the assessment and analysis. Assessment 
is the affinity of the interaction between the ligand and protein. The 
assessment process is estimated as the value of the free energy of 
binding ΔG binding. ΔG is used to predict the reaction spontaneity. If ΔG 
increasingly negative with greater value, the interaction of the ligand 
and the protein will be more constant and ligand conformation that the 
protein complex formed will be more stable.
In addition about ΔG, docking process also provides information 
about the orientation and position resulting from a ligand that 
acts as an inhibitor of the protein. This is evidenced by the shape 
conformation between ligands and proteins that interact in general 
through hydrogen bonding, hydrophobic interactions, and van der 
Waals bonding.
Table 1: Design of gallic acid analogs
No Compound R R1 R2 R3
1 Gallic acid H OH OH OH
2 Propyl gallate C3H7 OH OH OH
3 Allyl gallate C3H5 OH OH OH
4 Phenyl ethyl gallate C8H9 OH OH OH
5 Diallyl gallate C6H10 OH OH OH
6 4-methoxy propyl gallate C3H7 OH OCH3 OH
7 3,4-dimethoxypropyl gallate C3H7 OCH3 OCH3 OH
8 3,4,5-trimethoxypropyl gallate C3H7 OCH3 OCH3 OCH3
9 4-methoxyallyl gallate C3H5 OH OCH3 OH
10 3,4-dimethoxy allyl gallate C3H5 OCH3 OCH3 OH
11 3,4,5-trimethoxy allyl gallate C3H5 OCH3 OCH3 OCH3
12 4-methoxyphenyl ethyl gallate C8H9 OH OCH3 OH
13 3,4-dimethoxyphenyl ethyl gallate C8H9 OCH3 OCH3 OH
14 3,4,5-trimethoxyphenyl ethyl gallate C8H9 OCH3 OCH3 OCH3
15 Methyl gallate CH3 OH OH OH
16 4-methoxy methyl gallate CH3 OH OCH3 OH
17 3-4-dimethoxy methyl gallate CH3 OCH3 OCH3 OH
18 3,4,5-trimethoxy methyl gallate CH3 OCH3 OCH3 OCH3
19 4-methoxy gallate H OH OCH3 OH
20 3,4-dimethoxy gallic acid H OCH3 OCH3 OH
21 3,4,5-trimethoxy gallic acid H OCH3 OCH3 OCH3
22 Benzyl gallate C7H7 OH OH OH
23 4-methoxy benzyl gallate C7H7 OH OCH3 OH
24 3,4-dimethoxy benzyl gallate C7H7 OCH3 OH OH
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From the docking results, 23 gallic acid analogs screened for this study, 
five compounds with the best interaction with the BH3 domain of anti-
apoptotic Bcl-XL receptor are shown in Table 3.
The results showed that the five docking derived compounds that have 
a value ΔG smaller and the pKi value greater than gallic acid also have 
LogP value greater than gallic acid. This is consistent with previous 
studies showing that hydrophobic interactions play an important role 
in bonding between the ligand binding site cavity protein Bcl-XL. The 
site where the binding protein Bcl-XL broad ligand is a molecule made 
easy entry into it. Conformation best ligand into Bcl-XL cavity showed 
in Fig. 1.
The docking structure of the best five compounds is bound in a very 
similar pattern with the binding site of Bcl-XL receptor. The compounds 
also have similar volume and radius for the active binding site for 
defining the sphere. The compounds have different poses in the 
active site according to its number of hydrogen bond interactions. 
Interestingly, all the compounds have a good hydrogen bond interaction 
with the antiapoptotic Bcl-XL receptor.
As shown in Fig. 2, complex of gallic acid and the protein has three 
hydrogen bonds between the carbon of the benzene ring number 
three and four with the amino acid residues alanine (ALA108A) and 
glutamate (GLU 133A) Bcl-XL protein. Gallic acid acts as a hydrogen 
bond donor. Gallic acid ester derivative, propyl gallate has four hydrogen 
bonds, two hydrogen bonds as donor and the others as an acceptor (a). 
Amino acid residues involved in hydrogen bonding propyl gallate is 
GLU104A, Arg104A, Tyr105A. Three aliphatic carbon atoms in propyl 
provide hydrophobic interactions. In the complex between the benzyl 
gallate with the protein showed three hydrogen bond donor with 
GLU100A amino acid residues, and two hydrogen bond acceptors with 
amino acid residue ARG 104A dan TYR105A (b). Phenyl side chains 
undergo hydrophobic interactions with amino acid residues PHE195A, 
PHE101A, ALA97A, TRY199A, and VAL145A. Allyl gallate complex with 
the protein indicates a hydrogen bond donor interaction with amino 
acids GLU96A and one hydrogen bond acceptor with amino acids 
ARG208A (c). Allyl side chains undergo hydrophobic interactions with 
the amino acids VAL145A, PHE101A, and PHE195A. In the complex 
between diallyl gallate and protein, the type of interaction less when 
compared to the allyl gallate. Hydrophobic interactions between side 
chains on the allyl ester together with the allyl. However, the hydrogen 
bond on diallyl only one of hydrogen bond acceptor with amino acids 
Fig. 1: Complex of best ligand with Bcl-XL protein trough 
molecular docking analysis
Table 2: Lipinski properties of the five best gallic acid analogs
No Compound Molecular 
weight
HBD HBA LogP
1 Gallic acid 170.02 4 5 0.55
2 Propyl gallate 212.07 3 5 1.86
3 Benzyl gallate 246.05 3 5 2.25
4 Allyl gallate 210.05 3 5 1.64
5 Diallyl gallate 250.08 2 5 2.74
6 Phenyl ethyl gallate 274.08 3 5 2.82
HBA: Hydrogen bond acceptors, HBD: Hydrogen bond donors
Table 3: Molecular docking interaction of gallic acid analogs 
with Bcl-XL
No Compound ΔG (Kcal/Mol) pKi (µM)
1 Propyl gallate −7.5 1.31
2 Benzyl gallate −7.3 1.27
3 Diallyl gallate −7.2 1.25
4 Phenyl ethyl gallate −6.7 1.17
5 Allyl gallate −6.5 1.13
6 Gallic acid −5.5 0.96
Fig. 2: Interaction of the gallic acid analogs with the Bcl-XL receptor. (a) Propyl gallate, (b) benzyl gallate, (c) allyl gallate, (d) diallyl 
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ARG208A (d). Complex between ethyl phenyl gallate and protein 
indicate hydrophobic interactions between side chains of amino acid 
phenyl with ALA97A, VAL145A, PHE101A, and PHE195A (e). Hydrogen 
bonding interactions occur only one, that is, with GLU100A as a donor. 
Based on this data, derivatization of gallic acid provides additional 
hydrophobic interactions with the protein (f).
The BH3 domain of the proapoptotic protein is thought to be important 
for the induction of apoptosis. A small molecule interacts with the 
BH3 binding domain of Bcl-XL/Bcl-2 will function as Bcl-XL/Bcl-2 
antagonists and promote apoptosis. In connection to this context in our 
study the data set of five best compounds inhibiting Bcl-XL receptor 
also serves to bind to a lesser extent with BH3 binding groove of Bcl-
XL receptor. From the insight domain analysis, it is observed that 
compounds falls often in GLY94, ASP95, GLU96, PHE97, and GLU98 of 
the BH3 domain of Bcl-XL receptor.
Gallic acid which is polar compound show no hydrophobic interaction 
at the binding site of Bcl-XL. This is consistent with the expected that 
decrease polarity will improve the hydrophobic interactions.
CONCLUSION
Protein-ligand interaction studies, in silico from the docking results we 
conclude five gallic acid analogs have good interaction and inhibitory 
effect with the BH3 domain of antiapoptotic Bcl-XL receptor better than 
the lead compound, gallic acid. Hence, we can predict that these five 
compounds can be an agent for promoting apoptosis. However, this 
mechanism of prediction requires further in vitro and in vivo studies for 
the complete analysis of inducing apoptosis in cancerous cells.
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